Effect of Inertial Cavitation by Ultrasound Active Silica Nanoparticles on 2- and 3D Cellular Systems
Source abstract
Abstract
Macromolecular transport in tumors is often limited by tumor and matrix structure. These limitations can be addressed using focused ultrasound to apply mechanical force, but previous examples have used therapeutic levels that can damage tissue and risk off-target side effects. Instead, an acoustically interacting particle could reduce the levels of ultrasound required to enact tumor structure changes. Here, we used phospholipid coated hydrophobically modified mesoporous silica nanoparticles (PL-HMSNs) as cavitation nuclei to significantly reduce the intensities necessary to generate effects on cells and their surrounding matrix. First, we designed particles that retained acoustic activity in biological media over 24 h. These particles were then shown to bind to 2D cultures in as little as 15 min. Next, these particles demonstrated ablation of 2D cultures upon HIFU insonation. In 3D cultures, however, significant drops in fibronectin and cadherin content were observed while overall spheroid morphology and cell viability remained intact. This reduction in extracellular matrix allowed for greater accumulation and transport of a targeted affibody-enzyme therapeutic. Together these results suggest the possibility of using these nanoscale cavitation nuclei to reduce HIFU intensities needed to change tumor structure to enhance therapeutic transport.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ultrasound and Cavitation Phenomena · Ultrasound and Hyperthermia Applications · Bone Tissue Engineering Materials
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical and Biological Engineering
University of Colorado Boulder
Materials Science and Engineering Program
Biomedical Engineering Program
Funding
National Cancer Institute · Office of Postsecondary Education · Division of Chemical, Bioengineering, Environmental, and Transport Systems
References (63)
Show source-provided references
1. 10.1186/s13045-019-0818-210.1186/s13045-019-0818-2 ↗
2. 10.1021/acs.biomac.7b0006810.1021/acs.biomac.7b00068 ↗
3. 10.1039/D3BM01959D10.1039/D3BM01959D ↗
4. 10.1038/nbt.333010.1038/nbt.3330 ↗
5. 10.3390/biomedicines901001010.3390/biomedicines9010010 ↗
6. 10.1021/acs.biomac.4c0122510.1021/acs.biomac.4c01225 ↗
7. 10.1039/D4NA00823E10.1039/D4NA00823E ↗
8. 10.1371/journal.pone.011897710.1371/journal.pone.0118977 ↗
9. Stroomer J. W. · Clin. Cancer Res. · 2000 · 6 · 3046
10. 10.1016/j.jconrel.2018.06.01610.1016/j.jconrel.2018.06.016 ↗
11. 10.1080/10717544.2020.183110610.1080/10717544.2020.1831106 ↗
12. 10.1038/natrevmats.2016.1410.1038/natrevmats.2016.14 ↗
13. 10.3390/pharmaceutics1210097410.3390/pharmaceutics12100974 ↗
14. 10.1016/j.jconrel.2017.02.03510.1016/j.jconrel.2017.02.035 ↗
15. 10.1039/C8TB03034K10.1039/C8TB03034K ↗
16. 10.1002/hep.2410810.1002/hep.24108 ↗
17. 10.1186/s40164-025-00647-210.1186/s40164-025-00647-2 ↗
18. 10.3389/fimmu.2024.146760210.3389/fimmu.2024.1467602 ↗
19. 10.1136/jitc-2020-00180010.1136/jitc-2020-001800 ↗
20. 10.1007/s00259-024-06952-y10.1007/s00259-024-06952-y ↗
21. 10.1016/j.addr.2015.11.00110.1016/j.addr.2015.11.001 ↗
22. 10.3390/cancers1401023810.3390/cancers14010238 ↗
23. 10.1186/s12943-023-01744-810.1186/s12943-023-01744-8 ↗
24. 10.1080/17425247.2020.181473510.1080/17425247.2020.1814735 ↗
25. 10.1038/s41392-021-00544-010.1038/s41392-021-00544-0 ↗
26. 10.1158/0008-5472.CAN-03-147210.1158/0008-5472.CAN-03-1472 ↗
27. 10.1158/0008-5472.CAN-05-224210.1158/0008-5472.CAN-05-2242 ↗
28. 10.1128/iai.7.2.212-217.197310.1128/iai.7.2.212-217.1973 ↗
29. 10.1021/acs.molpharmaceut.8b0031910.1021/acs.molpharmaceut.8b00319 ↗
30. 10.1016/j.jconrel.2017.09.02210.1016/j.jconrel.2017.09.022 ↗
31. 10.1016/j.jmu.2014.02.00610.1016/j.jmu.2014.02.006 ↗
32. 10.1148/rycan.23007410.1148/rycan.230074 ↗
33. 10.1259/bjr.2017064110.1259/bjr.20170641 ↗
34. 10.1158/0008-5472.CAN-16-153610.1158/0008-5472.CAN-16-1536 ↗
35. 10.1186/s12935-022-02801-w10.1186/s12935-022-02801-w ↗
36. 10.2217/fon.11.11210.2217/fon.11.112 ↗
37. 10.3390/ijms1805094610.3390/ijms18050946 ↗
38. 10.1080/16501970175041960810.1080/165019701750419608 ↗
39. 10.1016/j.ultrasmedbio.2022.03.01010.1016/j.ultrasmedbio.2022.03.010 ↗
40. 10.1021/acs.chemmater.6b0263410.1021/acs.chemmater.6b02634 ↗
41. 10.1021/acsanm.3c0274710.1021/acsanm.3c02747 ↗
42. 10.1002/adfm.20200736310.1002/adfm.202007363 ↗
43. 10.34133/bmef.001610.34133/bmef.0016 ↗
44. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗
45. 10.1002/EXP.2021002310.1002/EXP.20210023 ↗
46. 10.1016/j.ultrasmedbio.2020.01.00210.1016/j.ultrasmedbio.2020.01.002 ↗
47. 10.1016/j.ultrasmedbio.2018.10.03310.1016/j.ultrasmedbio.2018.10.033 ↗
48. 10.1007/s12274-024-6845-510.1007/s12274-024-6845-5 ↗
49. 10.2217/nnm-2023-035810.2217/nnm-2023-0358 ↗
50. 10.1021/acsanm.4c0484310.1021/acsanm.4c04843 ↗
51. 10.1002/advs.20240760910.1002/advs.202407609 ↗
52. 10.1021/acsnano.5b0437810.1021/acsnano.5b04378 ↗
53. 10.1039/C8NH00340H10.1039/C8NH00340H ↗
54. 10.1039/C8NR00693H10.1039/C8NR00693H ↗
55. 10.1016/j.ultsonch.2025.10731610.1016/j.ultsonch.2025.107316 ↗
56. 10.1039/D5NR01091H10.1039/D5NR01091H ↗
57. 10.1016/j.cej.2017.12.05110.1016/j.cej.2017.12.051 ↗
58. 10.1007/978-1-61779-331-8_810.1007/978-1-61779-331-8_8 ↗
59. 10.1002/adfm.20241234410.1002/adfm.202412344 ↗
60. 10.1021/acsnano.2c0255810.1021/acsnano.2c02558 ↗
61. 10.1016/j.ultsonch.2015.05.03610.1016/j.ultsonch.2015.05.036 ↗
62. 10.1038/s41598-020-66994-810.1038/s41598-020-66994-8 ↗
63. 10.1039/D4BM00688G10.1039/D4BM00688G ↗